A Clinical Study to Determine the Safety and Efficacy of an Oral Supplementation of Bio-Immune®for Managing Upper Respiratory Tract Infection and Its Symptoms.

Exclusion Criteria

• •1\. The subject is currently diagnosed with active respiratory infections or diseases other than uncomplicated URTI that might require immediate medical attention or intervention will be excluded.
• •2\. The chest X-ray of the subject, performed within the past 28 days, reveals significant respiratory disorders or other serious conditions that might interfere with the study or necessitate medical intervention.
• •3\. Laboratory tests (blood and urinalysis) performed at the screening visit reveal significant infective or other serious conditions that could interfere with the study or necessitate medical intervention.
• •4\. The subject has known immunocompromising conditions such as HIV/AIDS, or those undergoing immunosuppressive therapy.
• •5\. The subject has other significant respiratory diseases (e.g., COPD, asthma, interstitial lung disease, active tuberculosis).
• •6\. The subject has uncontrolled or severe cardiovascular, renal, or hepatic conditions.
• •7\. The subject has participated in any other clinical trial within 30 days prior to the screening visit.
• •8\. The subject is pregnant/lactating, or is planning on become pregnant during the course of the study.
• •9\. The subject has known hypersensitivity or allergies to any component of the test treatment or similar botanical extracts are excluded.
• •10\. The subject is on regular medications known to interfere with the study outcomes (e.g., systemic corticosteroids, antiviral drugs) within 4 weeks before screening are excluded.
• •11\. The subject has any condition that, in the investigator's judgment, would compromise the subject's safety or study integrity.